You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

 

654 Results
Drug
Other Name(s): Votrient®
Quick Link(s):
Drug Monograph, Patient Info Sheet
Dec 2024
Regimen
Cancer Type:
Genitourinary, 
Renal cell / Kidney
Show More Show more tags
, Show Less Show fewer tags
Intent: Palliative
Funding:
Exceptional Access Program
    pazopanib - For first-line treatment of advanced or metastatic renal cell carcinoma of clear cell histology in patients with good performance status (ECOG 0-1), with specific criteria
Show More Show more tags
, Show Less Show fewer tags
Drugs Used:
pazopanib
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Dec 2024
Regimen
Cancer Type:
Sarcoma, 
Soft Tissue
Show More Show more tags
, Show Less Show fewer tags
Intent: Palliative
Drugs Used:
pazopanib (Unfunded)
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Dec 2024
Scientist, Surveillance Research, Acute and Hospital-Based Care, Ontario Health todd.norwood@ontariohealth.ca  
Chercheur, Recherche en matière de surveillance, Soins aigus et hospitaliers, Santé Ontario todd.norwood@ontariohealth.ca  
Drug
Other Name(s): Taxol®
Quick Link(s):
Drug Monograph, Patient Info Sheet
Nov 2024
Drug
Other Name(s): Imjudo®
Quick Link(s):
Drug Monograph, Patient Info Sheet
Apr 2024
Drug
Other Name(s): Herceptin® , Kanjinti™; Ogivri™; Trazimera™; Herzuma®; Ontruzant®
Quick Link(s):
Drug Monograph, Patient Info Sheet
Dec 2024
Drug
Other Name(s): Tecvayli®
Quick Link(s):
Drug Monograph, Patient Info Sheet
Jan 2025
Regimen
Cancer Type:
Lung, 
Non-Small Cell
Show More Show more tags
, Show Less Show fewer tags
Intent: Palliative
Drugs Used:
pemetrexed,
amivantamab (Unfunded)
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Jan 2025

Pages